Clinical Trial: Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07730528) titled 'Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)' on July 23.

Brief Summary: The goal of this study is to assess safety and efficacy of Humacyte's coronary tissue engineered vessel (CTEV) used as a bypass conduit in patients requiring multi vessel coronary artery bypass grafting (CABG).

The main question it aims to answer whether the CTEV is feasible as a conduit in CABG surgery.

Each participant will be implanted with a CTEV using standard surgical techniques and followed for up to 36 months fo...